Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07348276 · ClinicalTrials.gov registry record · Early Phase 1
First-in-Human Study for the Safety and Evaluation of Two 4R Tau Ligands as Potential PET Radioligands for Imaging Tau Protein in the Brain
A Early Phase 1 study of Healthy Participants and Progressive Supranuclear Palsy (PSP), sponsored by Invicro.
- Recruiting
- Registry status
- Early Phase 1
- Development phase
- 24
- Enrollment target
- 1
- Study location
NCT07348276 is a Early Phase 1 study of Healthy Participants and Progressive Supranuclear Palsy (PSP) that is actively recruiting participants, run by Invicro. The registered enrollment target is 24 participants, below the 65-participant average among 119 other Healthy Participants trials with a reported enrollment target (63% lower). The trial reports 1 study location across 1 state.
The verdict
NCT07348276, a Early Phase 1 study of Healthy Participants and Progressive Supranuclear Palsy (PSP), is actively recruiting participants, sponsored by Invicro.
- RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 24 participants
- Enrollment target
- 1
- Study location
Study Summary
This clinical study is being conducted to learn more about two new imaging drugs, called \[18F\]ABBV-964i and \[18F\]ABBV-965i, which are designed to help doctors see changes in the brain related to a condition called Progressive Supranuclear Palsy (PSP). PSP is a rare disease that affects movement, balance, and thinking. These drugs are used with a type of scan called PET (Positron Emission Tomography) to show areas of the brain where a protein called tau builds up. Tau buildup is linked to PSP and other brain diseases. The main goal of this study is to find out if these imaging drugs are safe for people and if they work well to show tau in the brain. The study will also look at how the drugs move through the body and how much radiation they give off. Researchers hope this information will help develop better tools for diagnosing PSP and tracking how it changes over time. Who can join? Adults who are healthy or who have PSP may be able to take part. Participants will have screening tests to make sure they qualify. What does participation involve? People in the study will have PET scans, blood tests, and other safety checks. Some participants will also have an MRI scan. The study is divided into three parts: Part A checks radiation levels in healthy volunteers, Part B looks at how the drugs work in the brain of PSP patients and healthy volunteers, and Part C (optional) repeats scans to see if results are consistent. Why is this important? There is currently no cure for PSP, and better imaging tools could help researchers develop new treatments. By joining this study, participants will help advance research that may improve care for people with PSP and similar conditions in the future.
Conditions Studied
Interventions
- DRUG [18F]ABBV-964i
- DRUG [18F]ABBV-965i
- DRUG Lead Candidate
Study Locations (1)
Connecticut
- Invicro (dba Perceptive) - New Haven
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2025-11-17 |
| Est. Completion | 2027-03 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07348276
The ClinicalTrials.gov registry entry for NCT07348276 describes a study currently listed as recruiting, categorized as Early Phase 1. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 65-participant average among 119 other Healthy Participants trials with a reported enrollment target (63% lower). The listed sponsor is Invicro, which has 14 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Healthy Participants appearing as the primary indexed condition, and to 3 interventions - of which [18F]ABBV-964i is the first listed.
NCT07348276 reports 1 study location spanning 1 distinct geographic area - top geographies include Connecticut.
Frequently Asked Questions
What is clinical trial NCT07348276 about?
NCT07348276 is a clinical study titled "First-in-Human Study for the Safety and Evaluation of Two 4R Tau Ligands as Potential PET Radioligands for Imaging Tau Protein in the Brain". This clinical study is being conducted to learn more about two new imaging drugs, called \[18F\]ABBV-964i and \[18F\]ABBV-965i, which are designed to help doctors see changes in the brain related to a condition called Progressive Supranuclear Palsy (PSP). PSP is a rare disease that affects movement,...
What is the current status of trial NCT07348276?
This trial is currently recruiting. It is a Early Phase 1 study. The enrollment target is 24 participants. The study started on 2025-11-17. Estimated completion is 2027-03.
What conditions does trial NCT07348276 study?
This clinical trial studies the following conditions: Healthy Participants, Progressive Supranuclear Palsy (PSP).
What interventions are being tested in trial NCT07348276?
The interventions under investigation include: [18F]ABBV-964i (DRUG), [18F]ABBV-965i (DRUG), Lead Candidate (DRUG).
Who is sponsoring clinical trial NCT07348276?
This trial is sponsored by Invicro, which has 14 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07348276 being conducted?
This trial has 1 study location across Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Healthy Participants
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Researching Economical Adjuvants to Cancer Therapy
RECRUITING · Early Phase 1
-
Single and Multiple Ascending Doses of NTX-253 in Healthy Participants and Participants With Stable Schizophrenia
RECRUITING · Early Phase 1
-
Renal Salt Handling in Postural Tachycardia Syndrome Following Dietary Dopa Administration
COMPLETED · Early Phase 1
-
Washington University WU 409: Immune Responses to Rabies Vaccine.
COMPLETED · Early Phase 1
-
A Study to Assess the Bioequivalence of Trastuzumab Via Different Subcutaneous Delivery Platforms in Healthy Male Participants
RECRUITING · Phase 1
-
Impact of Exogenous Ketones on Sleep and Breathing in Healthy Volunteers (K-SLEEP)
RECRUITING · Phase 1
Explore more on PlainTrial
Healthy Participants
All registered trials for this condition
Progressive Supranuclear Palsy (PSP)
All registered trials for this condition
Connecticut
All trials with a study site in Connecticut
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.